Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + P-GemOx + RT in Early-Stage Extranodal NK/T-Cell Lymphoma
NCT05254899Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2021
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Nov 2021; status: completed.
02
Drugs
tislelizumab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT05254899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254899.